Clinical Trials Study
Copyright ©The Author(s) 2025.
World J Cardiol. Apr 26, 2025; 17(4): 104396
Published online Apr 26, 2025. doi: 10.4330/wjc.v17.i4.104396
Table 3 Study participants selection criteria
Inclusion criteria
Non-inclusion criteria1
Exclusion criteria2
Participants age ≥ 40 yearsPregnancy and breastfeedingFailure of the stress test for reasons unrelated to heart disease
Participants with intact mental and physical activityDiabetes mellitusReluctance to continue participating in the study
Written consent to participate in the study, take blood samples, and anonymously publish the results of the studyPresence of signs of acute coronary syndrome (myocardial infarction in the prior 2 days), history of myocardial infarction
Participants in the experimental group are individuals with coronary artery disease, confirmed by stress-induced myocardial perfusion defect on the adenosine triphosphate stress myocardial perfusion computed tomographyActive infectious and non-infectious inflammatory diseases in the exacerbation phase
Respiratory diseases (bronchial asthma, chronic bronchitis, cystic fibrosis)
Acute thromboembolism of pulmonary artery branches
Aortic dissection
Critical anatomical heart defects
Active oncopathology
Decompensation phase of acute heart failure
Neurological pathology (Parkinson’s disease, multiple sclerosis, acute psychosis, Guillain-Barré syndrome)
Cardiac arrhythmias that do not allow exercise ECG testing (Wolff-Parkinson-White syndrome, Sick sinus syndrome, AV block of II-III-degree, persistent ventricular tachycardia)
Diseases of the musculoskeletal system that prevent passing a stress test (bicycle ergometry)
Allergic reaction to iodine and/or adenosine triphosphate